
==== Front
Geburtshilfe Frauenheilkd
Geburtshilfe Frauenheilkd
10.1055/s-00000020
Geburtsh Frauenheilk
Geburtshilfe und Frauenheilkunde
0016-5751
1438-8804
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

10.1055/a-2342-5218
GebFra Science
Letter to the Editor
Reply to: Letter to the Editor: Administration of Antenatal Corticosteroids: Optimal Timing
Berger Richard Prof. Dr. med.
Stelzl Patrick Dr.
Maul Holger Dr.
1 39639 Klinik für Gynäkologie und Geburtshilfe, Marienhaus Klinikum St. Elisabeth, Akademisches Lehrkrankenhaus der Universitäten Mainz und Maastricht, Neuwied, Germany
2 31197 Universitätsklinik für Gynäkologie, Geburtshilfe und gynäkologische Endokrinologie, Kepler Universitätsklinikum, Johannes Kepler Universität Linz, Linz, Austria
3 9161 Frauenkliniken, Asklepios Kliniken Barmbek, Wandsbek und Nord-Heidberg, Hamburg, Germany
Correspondence Prof. Dr. med. Richard Berger 39639 Klinik für Gynäkologie und Geburtshilfe, Marienhaus Klinikum St. Elisabeth, Akademisches Lehrkrankenhaus der Universitäten Mainz und Maastricht Friedrich-Ebert-Straße 5956564 NeuwiedGermanyrichard.berger@marienhaus.de
02 9 2024
9 2024
1 9 2024
84 9 877877
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
2024
The Author(s).
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
==== Body
pmc

We sincerely thank the authors of the letter to the editor for their interest in our work. The recommendations in the guidelines of the WAPM are almost identical to those in the German guideline on the prediction, prevention, and therapy of preterm birth 1 2 3 4 . However, beyond 34 + 0 weeks of gestation, we definitely see no indication for the application of ACS. According to the numbers from the ALPS trial, the NNT to prevent one patient with BPD is 1 : 200 5 . Otherwise, these children can be very well managed with high-flow nasal cannula and surfactant, if necessary.

In the present work, we have tried to provide the reader with a decision-making corridor that allows for optimizing the timing of ACS administration under various clinical settings beyond the guidelines mentioned above. While ACS administration is always indicated in women with PPROM, severe preeclampsia, fetuses with absent enddiastolic flow in the umbilical artery, or placental bleeding, great caution is warranted in patients with asymptomatic cervical insufficiency or preterm labor and a long cervix (≥ 15 mm).

Perhaps in the future the administration of ACS even at 30 weeks of gestation will be at stake. As cohort studies show a significant effect on IVH is very unlikely when ACS is administered beyond 30 weeks of gestation. The small effect on mortality before discharge beyond 30 weeks of gestation is clinically irrelevant with an NNT of approximately 1 : 800 6 . We agree with our colleagues Dagklis and Sen that further research work is urgently needed in this important field of perinatology for the benefit of the women and children entrusted to our care.

Conflict of Interest The authors declare that they have no conflict of interest.
==== Refs
References

1 Dagklis T Akolekar R Villalain C Management of preterm labor: Clinical practice guideline and recommendation by the WAPM-World Association of Perinatal Medicine and the PMF-Perinatal Medicine Foundation Eur J Obstet Gynecol Reprod Biol 2023 291 196 205 10.1016/j.ejogrb.2023.10.013 37913556
2 Dagklis T Sen C Tsakiridis I The use of antenatal corticosteroids for fetal maturation: clinical practice guideline by the WAPM-World Association of Perinatal Medicine and the PMF-Perinatal Medicine foundation J Perinat Med 2022 50 375 385 10.1515/jpm-2022-0066 35285217
3 Berger R Abele H Bahlmann F Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/025, September 2022) – Part 1 with Recommendations on the Epidemiology, Etiology, Prediction, Primary and Secondary Prevention of Preterm Birth Geburtshilfe Frauenheilkd 2023 83 547 568 10.1055/a-2044-0203 37152544
4 Berger R Abele H Bahlmann F Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, September 2022) – Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and on the Management of Preterm Premature Rupture of Membranes Geburtshilfe Frauenheilkd 2023 83 569 601 10.1055/a-2044-0345 37169014
5 Gyamfi-Bannerman C Thom EA Blackwell SC Antenatal Betamethasone for Women at Risk for Late Preterm Delivery N Engl J Med 2016 374 1311 1320 10.1056/NEJMoa1516783 26842679
6 Travers CP Clark RH Spitzer AR Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study BMJ 2017 356 j1039 10.1136/bmj.j1039 28351838
